Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Clin Genet ; 81(6): 590-4, 2012 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-21797849

RESUMO

Noonan and Cardio-facio-cutaneous (CFC) syndromes are characterized by typical dysmorphic features, cardiac defects, short stature, variable ectodermal anomalies, and intellectual disability. Both belong to the Ras/mitogen-activated protein kinase pathway group of disorders and clinical features overlap other related conditions, notably LEOPARD and Costello syndromes. KRAS mutations account for about 2% of reported Noonan and <5% of reported CFC cases. The mutation spectrum includes recurrent missense changes clustering in particular domains of the KRAS protein and conferring gain-of-function. We report three patients from two unrelated families with novel missense KRAS mutations, p.K147E and p.Y71H. Both mutations affect a residue which is highly conserved in KRAS and other RAS isoforms. One of the families includes a mother and son pair who represent the first report of a vertically transmitted KRAS mutation. In addition, the mother and son pair had peripheral neuropathy, complicated by Charcot arthropathy in the mother. An unusual phenotypic effect of the specific KRAS mutation or a coincidence of two independent disorders may be considered. KRAS mutation-associated phenotypes appear to be subject to considerable clinical heterogeneity. All three cases highlight the challenges of clinical assessment in KRAS mutation-positive patients, and the utility of molecular testing as an adjunct to diagnosis.


Assuntos
Mutação em Linhagem Germinativa , Fenótipo , Proteínas Proto-Oncogênicas/genética , Proteínas ras/genética , Artropatia Neurogênica/complicações , Artropatia Neurogênica/genética , Pré-Escolar , Diagnóstico Diferencial , Displasia Ectodérmica/complicações , Displasia Ectodérmica/genética , Fácies , Insuficiência de Crescimento/complicações , Insuficiência de Crescimento/genética , Feminino , Cardiopatias Congênitas/complicações , Cardiopatias Congênitas/genética , Humanos , Masculino , Proteínas Quinases Ativadas por Mitógeno/genética , Síndrome de Noonan/genética , Linhagem , Doenças do Sistema Nervoso Periférico/complicações , Doenças do Sistema Nervoso Periférico/genética , Proteínas Proto-Oncogênicas p21(ras)
2.
Oncogene ; 29(46): 6184-92, 2010 Nov 18.
Artigo em Inglês | MEDLINE | ID: mdl-20729911

RESUMO

Microtubule-interfering cancer drugs such as paclitaxel (PTX) often cause chemoresistance and severe side effects, including neurotoxicity. To explore potentially novel antineoplastic molecular targets, we investigated the cellular response of breast carcinoma cells to short hairpin(sh)RNA-mediated depletion of the centrosomal protein transforming acidic coiled coil (TACC) 3, an Aurora A kinase target expressed during mitosis. Unlike PTX, knockdown of TACC3 did not trigger a cell death response, but instead resulted in a progressive loss of the pro-apoptotic Bcl-2 protein Bim that links microtubule integrity to spindle poison-induced cell death. Interestingly, TACC3-depleted cells arrested in G1 through a cellular senescence program characterized by the upregulation of nuclear p21(WAF), downregulation of the retinoblastoma protein and extracellular signal-regulated kinase 1/2, formation of HP1γ (phospho-Ser83)-positive senescence-associated heterochromatic foci and increased senescence-associated ß-galactosidase activity. Remarkably, the onset of senescence following TACC3 knockdown was strongly accelerated in the presence of non-toxic PTX concentrations. Thus, we conclude that mitotic spindle stress is a major trigger of premature senescence and propose that the combined targeting of the centrosomal Aurora A-TACC3 axis together with drugs interfering with microtubule dynamics may efficiently improve the chemosensitivity of cancer cells.


Assuntos
Antineoplásicos Fitogênicos/farmacologia , Senescência Celular/efeitos dos fármacos , Proteínas Associadas aos Microtúbulos/fisiologia , Paclitaxel/farmacologia , Linhagem Celular Tumoral , Inibidor de Quinase Dependente de Ciclina p21/fisiologia , Doxorrubicina/farmacologia , MAP Quinases Reguladas por Sinal Extracelular/fisiologia , Humanos , Microtúbulos/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA